Sartorius Stedim stock gains ranking upgrade as analysts highlight upside potential

Published on 09/15/2026 at 13:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock is trading around EUR 184.30 on Euronext Paris as of September 14, 2026, while average analyst targets near EUR 240 underline upside potential. Recent ratings from Barclays and others frame the biotech supplier’s risk profile and sector role.

Fotorealistische Aufnahme einer sterilen Bioprozessanlage mit Einwegbeuteln und Bioreaktoren — Sartorius Stedim Biotech produziert sterile Einwegbeutel und Bioreaktoren für Biopharma-Hersteller weltweit, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech SA stock (ISIN FR0013154002) is quoted around EUR 184.30 on Euronext Paris as of September 14, 2026, placing the shares well below an average analyst price target of around EUR 240 for the biotech supplier.

Analyst targets signal upside room

According to an overview on Sartorius Stedim Biotech compiled by FinanzNachrichten and cited on September 14, 2026, the stock is listed with a current level of EUR 184.30 alongside an average analyst target of EUR 240, implying a potential gain of roughly 30 percent if the shares were to close that gap.

Recent data from finanzen.net show that Barclays Capital maintains an Overweight rating on Sartorius Stedim Biotech as of September 8, 2026, underscoring that at least some coverage houses see the current valuation as attractive relative to long term growth in bioprocessing equipment.

Share price and trading metrics

Price snapshots from finanzen.net put Sartorius Stedim Biotech at around EUR 184.40 in one view and a closing price of EUR 183.90 on the latest trading day, with an intraday range between EUR 183.30 and EUR 185.30, indicating modest day to day volatility in mid September 2026.

In the same overview, the stock’s one year range spans a low of EUR 150.40 and a high of EUR 223.20, so the latest level near EUR 184.00 sits roughly mid way between those extremes and below the recent peak, a positioning that investors often read as room for recovery if fundamentals and sector sentiment remain supportive.

Sector positioning and risk profile

Finanzen.net classifies Sartorius Stedim Biotech in the biotechnology equipment and supplies space and describes the risk profile as high since January 30, 2026, a reminder that even with upside to analyst targets, the shares can move markedly when sector news or interest rate expectations shift.

Performance figures from MarketScreener data linked to the company’s governance page indicate that a price of EUR 184.30 as of September 14, 2026 corresponds to a five day change of minus 1.89 percent and a year to date change of minus 10.45 percent, so the stock has given back some ground over 2026 despite the medium term support from growth in bioprocessing markets.

Closing price and investor view

At a closing price around EUR 183.90 on Euronext Paris as of the latest trading day in mid September 2026, Sartorius Stedim Biotech remains below its 52 week high of EUR 223.20, leaving quantitative upside versus both that technical reference point and the average analyst target of EUR 240 that frames many investors’ expectations.